About LRG Staff

This author has not yet filled in any details.
So far LRG Staff has created 565 blog entries.

Conversations with the Life Raft Group LIVE

Conversations with the Life Raft Group will debuted 4/2/2020 at 1 pm. Our first featured guest was Norman J. Scherzer, the Executive Director of the Life Raft Group. With his background at the CDC as Assistant Commissioner of Health for NYC, Norman is an excellent resource for discussing strategies for coping with COVID-19.

By |2020-07-09T17:49:22-04:00April 2nd, 2020|GIST Education, Patient Support, Webcast|

Survival in Advanced GIST Has Improved Over Time – LRG Science

In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.

By |2021-08-30T09:41:53-04:00April 1st, 2020|Drug Treatment, LRG Science, News, Research|

LRG Webcast Series: New Treatment Options for Advanced GIST & Concerns about the Coronavirus

During this webcast presentation, Dr. Michael Heinrich will discuss these two new treatment options for advanced GIST. Dr. Heinrich will explain how each of these drugs works to target mutations for which there has previously been no targeted treatment and discuss the current coronavirus outbreak.

By |2020-07-09T17:38:29-04:00March 24th, 2020|Drug Treatment, GIST Education, Webcast|

One Perspective on the BLU-285 Trial (avapritinib/Ayvakit)

LRG members Jennifer & Owen Moore give their perspective on participating in the Phase I BLU-285 trial at OSHU with Dr. Michael Heinrich. After three other drug treatment lines and faced with several growing tumors, the BLU-285 (avapritinib) trial was Owen’s best option.

By |2020-03-09T10:18:42-04:00February 28th, 2020|D842V, News, Newsletter|
Go to Top